-tinib
A tyrosine kinase inhibitor: a small molecule that blocks one of the enzymes cells use to pass on growth signals. Many are cancer drugs.
- Drugs ending in -tinib: 244
- Approved somewhere: 63
- With a US drug page: 66
- Stem
- -tinib
- Class
- Small molecules that block tyrosine kinases, the switches for many growth signals
- Sub-stems
- -brutinib, -citinib, -ertinib, -metinib, -trectinib
Approved and clinical-stage drugs in ChEMBL whose names ending in -tinib or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Afatinib | Approved | EGFR, ERBB2, ERBB4 | Epidermal growth factor receptor erbB1 inhibitor |
| Alectinib | Approved | ALK, RET, ALK, EML4 | ALK tyrosine kinase receptor inhibitor |
| Avapritinib | Approved | KIT, PDGFRA | Stem cell growth factor receptor inhibitor |
| Axitinib | Approved | Vascular endothelial growth factor receptor | Vascular endothelial growth factor receptor inhibitor |
| Bosutinib | Approved | ABL1, SRC, HCK, LYN and 1 more | Tyrosine-protein kinase ABL inhibitor |
| Brigatinib | Approved | ALK, EGFR | ALK tyrosine kinase receptor inhibitor |
| Cabozantinib | Approved | KDR, MET | Vascular endothelial growth factor receptor 2 inhibitor |
| Capmatinib | Approved | MET | Hepatocyte growth factor receptor inhibitor |
| Ceritinib | Approved | ALK, ALK, EML4, ALK, NPM1 | ALK tyrosine kinase receptor inhibitor |
| Crizotinib | Approved | MET, ALK, ALK, EML4, ALK, NPM1 and 2 more | Hepatocyte growth factor receptor inhibitor |
| Erdafitinib | Approved | Fibroblast growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Erlotinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Fedratinib | Approved | FLT3, JAK2 | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Fostamatinib | Approved | SYK | Tyrosine-protein kinase SYK inhibitor |
| Fruquintinib | Approved | Vascular endothelial growth factor receptor | Vascular endothelial growth factor receptor inhibitor |
| Futibatinib | Approved | Fibroblast growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Gefitinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Gilteritinib | Approved | FLT3, AXL | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Imatinib | Approved | ABL1, PDGFRB, KIT, ABL1, BCR | Tyrosine-protein kinase ABL inhibitor |
| Infigratinib | Approved | Fibroblast growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Lapatinib | Approved | ERBB2, EGFR | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Lenvatinib | Approved | Vascular endothelial growth factor receptor | Vascular endothelial growth factor receptor inhibitor |
| Lorlatinib | Approved | ALK, ALK, EML4 | ALK tyrosine kinase receptor inhibitor |
| Momelotinib | Approved | JAK1, JAK2, ACVR1 | Tyrosine-protein kinase JAK1 inhibitor |
| Neratinib | Approved | EGFR, ERBB2, ERBB4 | Epidermal growth factor receptor erbB1 inhibitor |
| Pacritinib | Approved | JAK2, FLT3, ACVR1, IRAK1 | Tyrosine-protein kinase JAK2 inhibitor |
| Pemigatinib | Approved | FGFR2, FGFR3, FGFR1 | Fibroblast growth factor receptor 2 inhibitor |
| Pexidartinib | Approved | CSF1R, FLT3, KIT | Macrophage colony stimulating factor receptor inhibitor |
| Ponatinib | Approved | ABL1, BCR | Bcr/Abl fusion protein inhibitor |
| Pralsetinib | Approved | RET, CCDC6, RET, KIF5B, RET | Tyrosine-protein kinase receptor RET inhibitor |
| Quizartinib | Approved | CSF1R, FLT3, KIT, PDGFRA, PDGFRB and 1 more | Macrophage colony stimulating factor receptor inhibitor |
| Ripretinib | Approved | KIT, PDGFRA | Stem cell growth factor receptor inhibitor |
| Selpercatinib | Approved | RET, KIF5B, RET, CCDC6, RET | Tyrosine-protein kinase receptor RET inhibitor |
| Sunitinib | Approved | CSF1R, KIT, FLT3, PDGFRA, PDGFRB and 7 more | Macrophage colony stimulating factor receptor inhibitor |
| Tepotinib | Approved | MET | Hepatocyte growth factor receptor inhibitor |
| Tucatinib | Approved | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Ensartinib | Phase 3 | ALK | ALK tyrosine kinase receptor inhibitor |
| Pimicotinib | Phase 3 | — | — |
| Vimseltinib | Phase 3 | — | — |
| Zidesamtinib | Phase 2 | — | — |
| Lirafugratinib | Phase 1 | — | — |
| Dacomitinib anhydrous | Approved | EGFR, ERBB2, ERBB4 | Epidermal growth factor receptor erbB1 inhibitor |
| Dasatinib anhydrous | Approved | ABL1, PDGFRB, KIT, EPHA2 and 2 more | Tyrosine-protein kinase ABL inhibitor |
| Filgotinib | Approved | JAK1, JAK2, TYK2, JAK3 | Tyrosine-protein kinase JAK1 inhibitor |
| Masitinib | Approved | FGFR3, KIT, PDGFRA, PDGFRB | Fibroblast growth factor receptor 3 inhibitor |
| Nilotinib | Approved | ABL1, ABL1, BCR | Tyrosine-protein kinase ABL inhibitor |
| Olmutinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Ruxolitinib | Approved | JAK1, JAK2, JAK3, TYK2 | Tyrosine-protein kinase JAK1 inhibitor |
| Catequentinib | Phase 3 | KDR, FLT4, KIT, PDGFRB | Vascular endothelial growth factor receptor 2 inhibitor |
| Defactinib | Phase 3 | PTK2, PTK2B | Focal adhesion kinase 1 inhibitor |
| Dovitinib | Phase 3 | FGFR3, FLT3, KIT, PDGFRA, PDGFRB and 1 more | Fibroblast growth factor receptor 3 inhibitor |
| Entospletinib | Phase 3 | SYK | Tyrosine-protein kinase SYK inhibitor |
| Famitinib | Phase 3 | KIT, FLT1, FLT3, PDGFRA, PDGFRB and 2 more | Stem cell growth factor receptor inhibitor |
| Flumatinib | Phase 3 | ABL1 | Tyrosine-protein kinase ABL inhibitor |
| Icotinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Lestaurtinib | Phase 3 | FLT3, JAK2, NTRK1, NTRK2 and 2 more | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Linsitinib | Phase 3 | IGF1R, INSR | Insulin-like growth factor I receptor inhibitor |
| Naquotinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Olverembatinib | Phase 3 | ABL1, BCR | Bcr/Abl fusion protein inhibitor |
| Orantinib | Phase 3 | Fibroblast growth factor receptor, PDGFRA, PDGFRB, KDR | Fibroblast growth factor receptor inhibitor |
| Poziotinib | Phase 3 | Epidermal growth factor receptor | Epidermal growth factor receptor inhibitor |
| Pyrotinib | Phase 3 | EGFR, ERBB2 | Epidermal growth factor receptor erbB1 inhibitor |
| Radotinib | Phase 3 | ABL1, BCR | Bcr/Abl fusion protein inhibitor |
| Rociletinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Ruserontinib | Phase 3 | EGFR, FLT3, ABL1 | Epidermal growth factor receptor erbB1 inhibitor |
| Savolitinib | Phase 3 | MET | Hepatocyte growth factor receptor inhibitor |
| Seralutinib | Phase 3 | KIT, PDGFRA, PDGFRB, CSF1R | Stem cell growth factor receptor inhibitor |
| Sitravatinib | Phase 3 | — | — |
| Surufatinib | Phase 3 | FGFR1, Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 inhibitor |
| Tesevatinib | Phase 3 | EPHB4, EGFR, ERBB2 | Ephrin type-B receptor 4 inhibitor |
| Tinengotinib | Phase 3 | — | — |
| Tivantinib | Phase 3 | MET | Hepatocyte growth factor receptor inhibitor |
| Zanzalintinib | Phase 3 | — | — |
| Adrixetinib | Phase 2 | — | — |
| Allitinib | Phase 2 | EGFR, ERBB2 | Epidermal growth factor receptor erbB1 inhibitor |
| Amuvatinib | Phase 2 | FLT3, KIT, MET, PDGFRA | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Bafetinib | Phase 2 | ABL1, LYN | Tyrosine-protein kinase ABL inhibitor |
| Bemcentinib | Phase 2 | AXL | Tyrosine-protein kinase receptor UFO inhibitor |
| Bezuclastinib | Phase 2 | — | — |
| Canlitinib | Phase 2 | — | — |
| Cerdulatinib | Phase 2 | SYK, JAK1, JAK3, TYK2 | Tyrosine-protein kinase SYK inhibitor |
| Dalmelitinib | Phase 2 | — | — |
| Decernotinib | Phase 2 | JAK3 | Tyrosine-protein kinase JAK3 inhibitor |
| Denfivontinib | Phase 2 | — | — |
| Derazantinib | Phase 2 | Fibroblast growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Edicotinib | Phase 2 | CSF1R | Macrophage colony stimulating factor receptor inhibitor |
| Elenestinib | Phase 2 | — | — |
| Enrupatinib | Phase 2 | — | — |
| Fanregratinib | Phase 2 | — | — |
| Fexagratinib | Phase 2 | Fibroblast growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Foretinib | Phase 2 | FLT3, KIT, MET, PDGFRA, PDGFRB and 2 more | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Gandotinib | Phase 2 | JAK2 | Tyrosine-protein kinase JAK2 inhibitor |
| Glesatinib | Phase 2 | MET, MST1R, Vascular endothelial growth factor receptor, TEK | Hepatocyte growth factor receptor inhibitor |
| Gumarontinib | Phase 2 | — | — |
| Ifebemtinib | Phase 2 | PTK2 | Focal adhesion kinase 1 inhibitor |
| Lunbotinib | Phase 2 | — | — |
| Merestinib | Phase 2 | MET | Hepatocyte growth factor receptor inhibitor |
| Mivavotinib | Phase 2 | SYK | Tyrosine-protein kinase SYK inhibitor |
| Mobinitinib | Phase 2 | — | — |
| Narmafotinib | Phase 2 | — | — |
| Nazartinib | Phase 2 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Nefextinib | Phase 2 | — | — |
| Ningetinib | Phase 2 | MET, KDR, MERTK, FLT3 and 1 more | Hepatocyte growth factor receptor inhibitor |
| Oritinib | Phase 2 | — | — |
| Pegcantratinib | Phase 2 | NTRK1 | Nerve growth factor receptor Trk-A inhibitor |
| Pelitinib | Phase 2 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Poseltinib | Phase 2 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Resencatinib | Phase 2 | — | — |
| Resigratinib | Phase 2 | — | — |
| Risvodetinib | Phase 2 | — | — |
| Rogaratinib | Phase 2 | Fibroblast growth factor receptor | Fibroblast growth factor receptor inhibitor |
| Sapitinib | Phase 2 | ERBB2, ERBB3, EGFR | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Saracatinib | Phase 2 | ABL1, SRC | Tyrosine-protein kinase ABL inhibitor |
| Segigratinib | Phase 2 | — | — |
| Soxataltinib | Phase 2 | — | — |
| Tamnorzatinib | Phase 2 | — | — |
| Tandutinib | Phase 2 | FLT3, KIT, PDGFRB | Tyrosine-protein kinase receptor FLT3 inhibitor |
| Tarloxotinib | Phase 2 | Epidermal growth factor receptor | Epidermal growth factor receptor inhibitor |
| Telatinib | Phase 2 | KIT, PDGFRB, KDR, FLT4 | Stem cell growth factor receptor inhibitor |
| Unecritinib | Phase 2 | — | — |
| Vamotinib | Phase 2 | — | — |
| Varlitinib | Phase 2 | EGFR, ERBB2 | Epidermal growth factor receptor erbB1 inhibitor |
| Veonetinib | Phase 2 | — | — |
| Vodobatinib | Phase 2 | ABL1, ABL1, BCR | Tyrosine-protein kinase ABL inhibitor |
| Altiratinib | Phase 1 | MET, TEK, KDR, Neurotrophic tyrosine kinase receptor | Hepatocyte growth factor receptor inhibitor |
| Conteltinib | Phase 1 | PTK2, IGF1R, ALK, PTK2B | Focal adhesion kinase 1 inhibitor |
| Dubermatinib | Phase 1 | — | — |
| Elzovantinib | Phase 1 | — | — |
| Enbezotinib | Phase 1 | — | — |
| Epitinib | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Fisogatinib | Phase 1 | — | — |
| Golvatinib | Phase 1 | MET, KDR | Hepatocyte growth factor receptor inhibitor |
| Henatinib | Phase 1 | KDR | Vascular endothelial growth factor receptor 2 inhibitor |
| Luxeptinib | Phase 1 | — | — |
| Mubritinib | Phase 1 | ERBB2 | Receptor protein-tyrosine kinase erbB-2 inhibitor |
| Rebastinib | Phase 1 | ABL1 | Tyrosine-protein kinase ABL inhibitor |
| Simotinib | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Soquelitinib | Phase 1 | — | — |
| Sotuletinib | Phase 1 | — | — |
| Tafetinib | Phase 1 | — | — |
| Theliatinib | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Tuspetinib | Phase 1 | — | — |
| Vebreltinib | Phase 1 | — | — |
| Zeteletinib | Phase 1 | — | — |
| Puquitinib | — | PI3-kinase class I, EGFR, KDR, PDGFRB | PI3-kinase class I inhibitor |
| Ibrutinib | Approved | BTK | Tyrosine-protein kinase BTK inhibitor |
| Pirtobrutinib | Approved | BTK | Tyrosine-protein kinase BTK inhibitor |
| Zanubrutinib | Approved | BTK | Tyrosine-protein kinase BTK inhibitor |
| Remibrutinib | Phase 3 | — | — |
| Rilzabrutinib | Phase 3 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Acalabrutinib | Approved | BTK | Tyrosine-protein kinase BTK inhibitor |
| Evobrutinib | Phase 3 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Fenebrutinib | Phase 3 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Nemtabrutinib | Phase 3 | — | — |
| Orelabrutinib | Phase 3 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Tolebrutinib | Phase 3 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Atuzabrutinib | Phase 2 | — | — |
| Cinsebrutinib | Phase 2 | — | — |
| Civorebrutinib | Phase 2 | — | — |
| Edralbrutinib | Phase 2 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Elsubrutinib | Phase 2 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Milrebrutinib | Phase 2 | — | — |
| Rocbrutinib | Phase 2 | — | — |
| Sofnobrutinib | Phase 2 | — | — |
| Spebrutinib | Phase 2 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Tirabrutinib | Phase 2 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Branebrutinib | Phase 1 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Vecabrutinib | Phase 1 | BTK | Tyrosine-protein kinase BTK inhibitor |
| Abrocitinib | Approved | JAK1 | Tyrosine-protein kinase JAK1 inhibitor |
| Baricitinib | Approved | JAK1, JAK2 | Tyrosine-protein kinase JAK1 inhibitor |
| Ritlecitinib | Approved | JAK3, TEC family kinase | Tyrosine-protein kinase JAK3 inhibitor |
| Tofacitinib | Approved | Janus Kinase (JAK) | Janus Kinase (JAK) inhibitor |
| Upadacitinib | Approved | TYK2, JAK3, JAK2, JAK1 | Tyrosine-protein kinase TYK2 inhibitor |
| Brepocitinib | Phase 3 | TYK2, JAK1 | Tyrosine-protein kinase TYK2 inhibitor |
| Delgocitinib | Phase 3 | Janus Kinase (JAK) | Janus Kinase (JAK) inhibitor |
| Cravacitinib | Approved | TYK2 | Tyrosine-protein kinase TYK2 negative allosteric modulator |
| Itacitinib | Phase 3 | JAK1 | Tyrosine-protein kinase JAK1 inhibitor |
| Ivarmacitinib | Phase 3 | — | — |
| Peficitinib | Phase 3 | Janus Kinase (JAK) | Janus Kinase (JAK) inhibitor |
| Povorcitinib | Phase 3 | — | — |
| Zasocitinib | Phase 3 | — | — |
| Cenacitinib | Phase 2 | — | — |
| Envucitinib | Phase 2 | — | — |
| Frevecitinib | Phase 2 | — | — |
| Girocitinib | Phase 2 | — | — |
| Golidocitinib | Phase 2 | JAK1 | Tyrosine-protein kinase JAK1 inhibitor |
| Gusacitinib | Phase 2 | Janus Kinase (JAK), SYK | Janus Kinase (JAK) inhibitor |
| Ifidancitinib | Phase 2 | — | — |
| Izencitinib | Phase 2 | Janus Kinase (JAK) | Janus Kinase (JAK) inhibitor |
| Lepzacitinib | Phase 2 | — | — |
| Lomecitinib | Phase 2 | — | — |
| Pumecitinib | Phase 2 | — | — |
| Ropsacitinib | Phase 2 | TYK2 | Tyrosine-protein kinase TYK2 inhibitor |
| Rovadicitinib | Phase 2 | — | — |
| Solcitinib | Phase 2 | JAK1 | Tyrosine-protein kinase JAK1 inhibitor |
| Zemprocitinib | Phase 2 | — | — |
| Milpecitinib | Phase 1 | — | — |
| Nezulcitinib | Phase 1 | Janus Kinase (JAK) | Janus Kinase (JAK) inhibitor |
| Oclacitinib | — | Janus kinase 1 | Janus kinase 1 inhibitor |
| Lazertinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Mobocertinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Osimertinib | Approved | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Sunvozertinib | Phase 3 | — | — |
| Sevabertinib | Phase 2 | — | — |
| Zongertinib | Phase 1 | — | — |
| Abivertinib | Phase 3 | EGFR, BTK | Epidermal growth factor receptor erbB1 inhibitor |
| Aumolertinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Firmonertinib | Phase 3 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Rezivertinib | Phase 3 | — | — |
| Befotertinib | Phase 2 | — | — |
| Canertinib | Phase 2 | EGFR, ERBB2, ERBB4 | Epidermal growth factor receptor erbB1 inhibitor |
| Mifanertinib | Phase 2 | — | — |
| Sacibertinib | Phase 2 | — | — |
| Tigozertinib | Phase 2 | — | — |
| Ulixertinib | Phase 2 | MAPK3, MAPK1 | MAP kinase ERK1 inhibitor |
| Mavelertinib | Phase 1 | EGFR | Epidermal growth factor receptor erbB1 inhibitor |
| Pebezertinib | Phase 1 | — | — |
| Ravoxertinib | Phase 1 | MAPK3, MAPK1 | MAP kinase ERK1 inhibitor |
| Tuxobertinib | Phase 1 | ERBB2, EGFR | Receptor protein-tyrosine kinase erbB-2 negative allosteric modulator |
| Binimetinib | Approved | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Cobimetinib | Approved | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Trametinib | Approved | MAP2K2, MAP2K1, MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 2 inhibitor |
| Mirdametinib | Phase 2 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Selumetinib | Approved | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Avutometinib | Phase 3 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Tunlametinib | Phase 3 | — | — |
| Gamcemetinib | Phase 2 | — | — |
| Luvometinib | Phase 2 | — | — |
| Nedometinib | Phase 2 | — | — |
| Ralimetinib | Phase 2 | MAPK14 | MAP kinase p38 alpha inhibitor |
| Refametinib | Phase 2 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Zapnometinib | Phase 2 | — | — |
| Zunsemetinib | Phase 2 | — | — |
| Pexmetinib | Phase 1 | MAPK14, TEK | MAP kinase p38 alpha inhibitor |
| Entrectinib | Approved | Neurotrophic tyrosine kinase receptor, ROS1, ALK | Neurotrophic tyrosine kinase receptor inhibitor |
| Larotrectinib | Approved | Neurotrophic tyrosine kinase receptor | Neurotrophic tyrosine kinase receptor inhibitor |
| Repotrectinib | Approved | NTRK1, NTRK2, ROS1, NTRK3 and 2 more | Nerve growth factor receptor Trk-A inhibitor |
| Anizatrectinib | Phase 2 | — | — |
| Boditrectinib | Phase 2 | — | — |
| Emzeltrectinib | Phase 2 | — | — |
| Taletrectinib | Phase 2 | ROS1, Neurotrophic tyrosine kinase receptor | Proto-oncogene tyrosine-protein kinase ROS inhibitor |
| Paltimatrectinib | Phase 1 | — | — |
| Selitrectinib | Phase 1 | Neurotrophic tyrosine kinase receptor | Neurotrophic tyrosine kinase receptor inhibitor |
| Zurletrectinib | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO